Social Anxiety Disorder Clinical Trial
Official title:
Efficacy, Tolerability and Safety of a Smartphone-delivered, Fully Automatic Cognitive Behavioural Therapy Programme for Social Anxiety
Verified date | August 2023 |
Source | Aya Technologies Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present study is a randomised controlled trial that seeks to investigate the efficacy and safety of the Alena app as a treatment for social anxiety disorder.
Status | Completed |
Enrollment | 250 |
Est. completion date | June 7, 2023 |
Est. primary completion date | June 7, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: - Scored over 30 on the SPIN (indicating at least moderate social anxiety) - Aged 18 or over - Fluent in English - Has access to a smartphone (iOS or Android) and the internet - UK resident Exclusion criteria: - Currently receiving therapy for their mental health - Mental health medication has changed (dosage or presence) in the last 8 weeks - Scores over 7 on the AUDIT-C and/or yes on either drug dependence question taken from the DUDIT (indicating drug or alcohol abuse) - Previous experience with the Alena app through prior studies or user testing |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Aya Technologies Limited | London |
Lead Sponsor | Collaborator |
---|---|
Aya Technologies Limited |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Social Phobia Inventory (SPIN) | The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear, avoidance and physiological components. | Change from baseline SPIN at 8 weeks | |
Primary | Change in Work and Social Adjustment Scale (WSAS) | The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day activities, such as work, home management and social leisure activities. | Change from baseline WSAS at 8 weeks | |
Secondary | Change in Social Phobia Inventory (SPIN) | The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear, | Change from SPIN level at the end of the intervention period at 4 weeks later | |
Secondary | Work and Social Adjustment Scale (WSAS) | The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day | At the follow-up point of 4 weeks after the end of the intervention period. | |
Secondary | Serious adverse events | Serious adverse events are defined as those that meet the criteria for ISO:14155(A:14) | Within the intervention period of 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00485615 -
An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia
|
Phase 2 | |
Completed |
NCT00773162 -
Flushing in Social Anxiety Disorder on Seroquel
|
Phase 3 |